PD-L1

PD-L1 Testing

Immune Checkpoint Inhibitors

Overexpression of PD-L1 has been observed in many carcinomas including lung, urothelial, gastroesphageal junction, Squamous Cell Carcinoma of the Head and Neck (SCCHN), cervical, triple-negative breast cancer (TNBC) and melanoma

Tumor PD-L1 expression levels have been shown to be a predictive marker with response to several anti-PD1 antibodies1,2

PD-L1 Testing

Immune Checkpoint Inhibitor Therapies

Sample TypeDrug Under ConsiderationPD-L1 Testing
Cervical CancerpembrolizumabDAKO (22C3) Companion Diagnostic Test1
EspohagealpembrolizumabDAKO (22C3) Companion Diagnostic Test1
Gastric / Gastroesophageal
Junction (GEJ) Adenocarcinoma
pembrolizumabDAKO (22C3) Companion Diagnostic Test1
MelanomanivolumabTesting not required
MelanomapembrolizumabTesting not required3
NSCLC - AdencocarcinomaatezolizumabVENTANA® (SP142) Complementary Diagnostic Test4
NSCLC - AdencocarcinomanivolumabDAKO (28-8) Complimentary Test5-7
NSCLC - AdencocarcinomapembrolizumabDAKO (22C3) Companion Diagnostic Test3
NSCLC - SquamousatezolizumabVENTANA® (SP142) Complementary Diagnostic Test4
NSCLC - SquamousnivolumabTesting not required6
NSCLC - SquamouspembrolizumabDAKO (22C3) Companion Diagnostic Test3
Squamous Cell Carcinoma of the Head and Neck (SCCHN)nivolumabDAKO (28-8) Complimentary Test8
Squamous Cell Carcinoma of the Head and Neck (SCCHN)pembrolizumabDAKO (22C3) Companion Diagnostic Test1
Triple Negative Breast Cancer (TNBC)atezolizumabVENTANA® Companion Diagnostic Test9
Urothelial CarcinomaatezolizumabVENTANA® (SP142) Complementary Diagnostic Test9
Urothelial CarcinomanivolumabDAKO (28-8) Complimentary Test8
Urothelial CarcinomapembrolizumabDAKO (22C3) Companion Diagnostic Test1

sample type

Cervical Cancer

Drug Under Consideration: pembrolizumab
PD-L1 Testing: DAKO (22C3) Companion Diagnostic Test1


sample type

Espohageal

Drug Under Consideration: pembrolizumab
PD-L1 Testing: DAKO (22C3) Companion Diagnostic Test1


sample type

Gastric / Gastroesophageal
Junction (GEJ) Adenocarcinoma

Drug Under Consideration: pembrolizumab
PD-L1 Testing: DAKO (22C3) Companion Diagnostic Test1


sample type

Melanoma

Drug Under Consideration: nivolumab
PD-L1 Testing: Testing not required

Drug Under Consideration: pembrolizumab
PD-L1 Testing: Testing not required3


sample type

NSCLC - Adencocarcinoma

Drug Under Consideration: atezolizumab
PD-L1 Testing: VENTANA® (SP142) Complementary Diagnostic Test4

Drug Under Consideration: nivolumab
PD-L1 Testing: DAKO (28-8) Complimentary Test5-7

Drug Under Consideration: pembrolizumab
PD-L1 Testing: DAKO (22C3) Companion Diagnostic Test3


sample type

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Drug Under Consideration: nivolumab
PD-L1 Testing: DAKO (28-8) Complimentary Test8

Drug Under Consideration: pembrolizumab
PD-L1 Testing: DAKO (22C3) Companion Diagnostic Test1


sample type

Triple Negative Breast Cancer (TNBC)

Drug Under Consideration: atezolizumab​​​​​​​
PD-L1 Testing: VENTANA® Companion Diagnostic Test9


sample type

Urothelial Carcinoma

Drug Under Consideration: atezolizumab​​​​​​​
PD-L1 Testing: VENTANA® (SP142) Complementary Diagnostic Test9

Drug Under Consideration: nivolumab​​​​​​​
PD-L1 Testing: DAKO (28-8) Complimentary Test8

Drug Under Consideration: pembrolizumab​​​​​​​
PD-L1 Testing: DAKO (22C3) Companion Diagnostic Test1